You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
|
|---|---|
| Published in |
Alzheimer's Research & Therapy, February 2017
|
| DOI | 10.1186/s13195-017-0237-y |
| Pubmed ID | |
| Authors |
Nophar Geifman, Roberta Diaz Brinton, Richard E. Kennedy, Lon S. Schneider, Atul J. Butte |
| Abstract |
Despite substantial research and development investment in Alzheimer's disease (AD), effective therapeutics remain elusive. Significant emerging evidence has linked cholesterol, β-amyloid and AD, and several studies have shown a reduced risk for AD and dementia in populations treated with statins. However, while some clinical trials evaluating statins in general AD populations have been conducted, these resulted in no significant therapeutic benefit. By focusing on subgroups of the AD population, it may be possible to detect endotypes responsive to statin therapy. Here we investigate the possible protective and therapeutic effect of statins in AD through the analysis of datasets of integrated clinical trials, and prospective observational studies. Re-analysis of AD patient-level data from failed clinical trials suggested by trend that use of simvastatin may slow the progression of cognitive decline, and to a greater extent in ApoE4 homozygotes. Evaluation of continual long-term use of various statins, in participants from multiple studies at baseline, revealed better cognitive performance in statin users. These findings were supported in an additional, observational cohort where the incidence of AD was significantly lower in statin users, and ApoE4/ApoE4-genotyped AD patients treated with statins showed better cognitive function over the course of 10-year follow-up. These results indicate that the use of statins may benefit all AD patients with potentially greater therapeutic efficacy in those homozygous for ApoE4. |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 14% |
| Canada | 2 | 10% |
| United States | 1 | 5% |
| India | 1 | 5% |
| Poland | 1 | 5% |
| Philippines | 1 | 5% |
| Brazil | 1 | 5% |
| United Arab Emirates | 1 | 5% |
| Unknown | 10 | 48% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 71% |
| Practitioners (doctors, other healthcare professionals) | 3 | 14% |
| Science communicators (journalists, bloggers, editors) | 2 | 10% |
| Scientists | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 167 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| United States | 1 | <1% |
| Egypt | 1 | <1% |
| Unknown | 164 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 22 | 13% |
| Student > Bachelor | 22 | 13% |
| Student > Master | 21 | 13% |
| Researcher | 18 | 11% |
| Student > Doctoral Student | 17 | 10% |
| Other | 32 | 19% |
| Unknown | 35 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 17% |
| Neuroscience | 22 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 10% |
| Biochemistry, Genetics and Molecular Biology | 15 | 9% |
| Agricultural and Biological Sciences | 13 | 8% |
| Other | 24 | 14% |
| Unknown | 47 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 46. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 September 2023.
All research outputs
#917,059
of 25,728,855 outputs
Outputs from Alzheimer's Research & Therapy
#114
of 1,499 outputs
Outputs of similar age
#18,649
of 323,162 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 24 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.5. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,162 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.